160 related articles for article (PubMed ID: 30728413)
1. Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma.
Loosen SH; Hoening P; Puethe N; Luedde M; Spehlmann M; Ulmer TF; Cardenas DV; Roy S; Tacke F; Trautwein C; Neumann UP; Luedde T; Roderburg C
Sci Rep; 2019 Feb; 9(1):1489. PubMed ID: 30728413
[TBL] [Abstract][Full Text] [Related]
2. High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.
Loosen SH; Tacke F; Püthe N; Binneboesel M; Wiltberger G; Alizai PH; Kather JN; Paffenholz P; Ritz T; Koch A; Bergmann F; Trautwein C; Longerich T; Roderburg C; Neumann UP; Luedde T
Carcinogenesis; 2019 Aug; 40(8):947-955. PubMed ID: 30805627
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
[TBL] [Abstract][Full Text] [Related]
5. Serum Levels of Kisspeptin Are Elevated in Patients with Pancreatic Cancer.
Loosen SH; Luedde M; Lurje G; Spehlmann M; Paffenholz P; Ulmer TF; Tacke F; Vucur M; Trautwein C; Neumann UP; Luedde T; Roderburg C
Dis Markers; 2019; 2019():5603474. PubMed ID: 31772690
[TBL] [Abstract][Full Text] [Related]
6. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
7. Survivin expression and serum levels in pancreatic cancer.
Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W
World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480
[TBL] [Abstract][Full Text] [Related]
8. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
[TBL] [Abstract][Full Text] [Related]
9. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
10. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
[TBL] [Abstract][Full Text] [Related]
11. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma.
Poruk KE; Firpo MA; Huerter LM; Scaife CL; Emerson LL; Boucher KM; Jones KA; Mulvihill SJ
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2605-10. PubMed ID: 20729288
[TBL] [Abstract][Full Text] [Related]
12. Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma.
Rittmann MC; Hussung S; Braun LM; Klar RFU; Biesel EA; Fichtner-Feigl S; Fritsch R; Wittel UA; Ruess DA
Sci Rep; 2021 Apr; 11(1):7499. PubMed ID: 33820913
[TBL] [Abstract][Full Text] [Related]
13. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.
Karasek P; Gablo N; Hlavsa J; Kiss I; Vychytilova-Faltejskova P; Hermanova M; Kala Z; Slaby O; Prochazka V
Cancer Genomics Proteomics; 2018; 15(4):321-327. PubMed ID: 29976637
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
Zhao X; Cao D; Ren Z; Liu Z; Lv S; Zhu J; Li L; Lang R; He Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32701143
[TBL] [Abstract][Full Text] [Related]
15. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
16. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum levels of bone sialoprotein during ICU treatment predict long-term mortality in critically ill patients.
Luedde M; Roy S; Hippe HJ; Cardenas DV; Spehlmann M; Vucur M; Hoening P; Loosen S; Frey N; Trautwein C; Luedde T; Koch A; Tacke F; Roderburg C
Sci Rep; 2018 Jun; 8(1):9750. PubMed ID: 29950701
[TBL] [Abstract][Full Text] [Related]
18. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
19. Effects of bone sialoprotein on pancreatic cancer cell growth, invasion and metastasis.
Kayed H; Kleeff J; Keleg S; Felix K; Giese T; Berger MR; Büchler MW; Friess H
Cancer Lett; 2007 Jan; 245(1-2):171-83. PubMed ID: 16488077
[TBL] [Abstract][Full Text] [Related]
20. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
